Table 1.
Demographic and clinical characterization of PD patients and controls Mean ± SD are shown with associated p-value (non-parametric Wilcoxon T-testa | Wilcoxson T-test b | Chi squared test c).
| Control subjects (n = 15) |
PD patients (n = 15) |
p-value | |
|---|---|---|---|
| Gender (M:F) | 4: 11 | 11: 4 | 0.01 (*) C |
| Age | 57.8 ± 2.6 (range: 44–76) |
58.9 ± 9.2 (range: 45–71) |
0.40 a |
| SCOPA total | 5.6 ± 2.7 (range: 2–10) |
12.3 ± 9.2 (range: 2–32) |
0.03 (*) a |
| SCOPA GI | 0.9 ± 0.80 (range: 0–2) |
2.7 ± 2.29 (range: 0–8) |
0.02 (*) b |
| Disease duration (years) | - | 7.8 ± 3.9 (range: 2–17) |
|
| UPDRS III off (disease severity) |
- | 23.3 ± 10.0 (range: 12–46) |
|
| Age at onset (years) | - | 51.1 ± 9.4 (range: 36–69) |
|
| Hoehn-Yahr (off) | - | 2 (IQR: 2–5) |
|
| LED (mg) | - | 684.1 ± 388.5 (range: 205–1740) |
|
| MMSE | - | 29.6 ± 0.9 |
(*indicates a statistical difference p<0.05). For Hoehn-Yahr scores, median and interquartile range are shown.